Synthesis and preclinical evaluation of <SUP>11</SUP>C-labeled (6-aryl-1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridin-1-yl)acetamide for imaging GluN2B subunit of NMDA receptors
Jiyun Sun,Zhen Chen,Jiahui Chen,Hualong Fu,Tuo Shao,Lu Wang,Hao Xu,Ming-Rong Zhang,Steven Liang
2020-01-01
Abstract:1112 Objectives: GluN2B is the most studied subunit of N‑methyl‑D‑aspartate receptors (NMDARs), which are related to the pathologies of various central nervous system disorders and neurodegenerative diseases, such as Parkinson’s disease (PD), Alzheimer’s disease (AD), Schizophrenia and neuropathic pain [1]. However, the in vivo imaging of GluN2B subunit remains a challenge. Herein we attempt to develop novel probes for positron emission computed tomography (PET) imaging of the GluN2B subunit.
Methods: The synthesis of cold compound 5, 2-(6-(4-fluoro-3-methylphenyl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-N,N-dimethylacetamide, was achieved following a 3-step process [2]. The amidation of starting material 2-bromo-acetic acid 1 with methylamine in THF solution afforded the 2-bromo-N,N-dimethylacetamide 2. A SN2 reaction between amide 2 and 6-bromo-1H-pyrrolo[3,2-b]pyridine 3 in the presence of K2CO3 in DMF gave 2-(6-bromo-1H-pyrrolo[3,2-b]pyridin-1-yl)-N,N-dimethylacetamide 4 with a yield of 81%. Then Pd(dppf)Cl2-catalyzed cross-coupling between amide 4 and (4-fluoro-3-methylphenyl)boronic acid provided the title product. By following the same method, 11C-labeling precursor, 2-(6-(4-fluoro-3-methylphenyl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-N-methylacetamide 8, was obtained by replacing methylamine in THF solution with H2NMe·HCl. Radiosynthesis of [11C]5 was obtianed using [11C]CH3I with K2CO3 in DMSO at 130 oC from precursor 8. The brain uptake studies were conducted in mice after 1, 2, and 5 min post-injection.
Results: The cold compound 5 was obtained in total yield of 21% over 3 steps, and the corresponding precursor 8 was achieved in 18%. The biological assay of compound 5 in trifluoroacetate salt form has been reported with pIC50 = 6.3 ([3H] inhibition binding assay) [2].11C-methylation strategy delivered the tracer [11C]5 in 4% isolated radiochemical yield (non-decay corrected from [11C]CO2) with high radiochemical purity (>99%) and high specific activity of 17.7 GBq/μmol. The brain uptake study revealed that [11C]5 exhibited moderate standard uptake valves (SUVs) in mice brain with the values of 0.61, 0.55 and 0.50 at 1, 2, and 5 min post-injection, respectively.
Conclusions: We have successfully synthesized and radiolabeled a potent GluN2B-selective NMDA receptor antagonist [11C]5, which showed moderate brain uptake in mice brain. Further studies including radiolabeling of the analogous, blocking studies, ex in vivo biodistribution, and dynamic PET scan are on the way. References: [1] Cur Top Med. Chem. 2016, 16, 1830-1842; [2] US2018208595, 2018.